Drug giant Lilly backs Cambridge's Dicerna in $200M deal
October 29, 2018 at 06:00 AM EDT
The Cambridge biotech is eligible to earn up to $3.7 billion through the deal, with $200 million upfront.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.